//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
[email protected] dosed the first participants in LIBERTY, a phase 3 clinical trial evaluating the safety and tolerability of VYD2311, its investigational monoclonal antibody candidate for #COVID-19 prevention. #IDsky #Medsky www.contagionlive.com/view/invivyd...
1d
Invivyd has dosed the first participants in LIBERTY, a phase 3 trial comparing VYD2311 to an mRNA COVID vaccine and coadministration, as the BLA-enabling DECLARATION trial completes enrollment.
www.contagionlive.com
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311 | Contagion Live
Contagion®